Cogent Biosciences

COGT40

$10.38arrow_drop_down0.28%-$0.03

COGT40

$10.38

arrow_drop_down0.28%-$0.03

Performance History

Key Stats
Open	$10.39
Prev. Close	$10.21
EPS	-2.49
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	10.22	10.84
52 Week Range	3.67	12.45

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.49

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Cogent Biosciences (COGT)

Cogent Biosciences, Inc. (COGT) is a biotechnology company focused on the discovery and development of precision therapies for the treatment of genetically defined diseases. The company's mission is to improve the lives of patients with rare and serious diseases by advancing its innovative pipeline of targeted therapies. COGT is committed to developing treatments that address the underlying genetic mutations responsible for these diseases, with the goal of providing personalized medicine options for patients.

COGT's stock price history reflects the market's recognition of the company's potential. Over the past year, the stock has experienced significant growth, reaching new highs. This positive trend can be attributed to a combination of factors, including positive clinical trial results, successful fundraising efforts, and increased investor confidence in the company's pipeline. As a result, COGT has become an attractive investment option for those looking to capitalize on the growing biotechnology sector.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Headquarters: Waltham
Employees: 138
Exchange: NASDAQ

Keep an eye on Cogent Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Cogent Biosciences's (COGT) price per share?

The current price per share for Cogent Biosciences (COGT) is $10.38. The stock has seen a price change of -$0.03 recently, indicating a -0.29% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Cogent Biosciences (COGT)?

For Cogent Biosciences (COGT), the 52-week high is $12.45, which is 19.98% from the current price. The 52-week low is $3.67, the current price is 182.83% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Cogent Biosciences (COGT) a growth stock?

Cogent Biosciences (COGT) has shown an average price growth of -3.67% over the past three years. It has received a score of 61 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cogent Biosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Cogent Biosciences (COGT) stock price performance year to date (YTD)?

As of the latest data, Cogent Biosciences (COGT) has a year-to-date price change of 66.35%. Over the past month, the stock has experienced a price change of -7.73%. Over the last three months, the change has been 22.12%. Over the past six months, the figure is 41.22%.

help

Is Cogent Biosciences (COGT) a profitable company?

Cogent Biosciences (COGT) has a net income of -$192.41M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$208.13M. Furthermore, the EBITDA is -$242.22M.

help

What is the market capitalization of Cogent Biosciences (COGT)?

Cogent Biosciences (COGT) has a market capitalization of $1.14B. The average daily trading volume is 10.33, indicating the stock's liquidity and investor engagement.

News

Jun 28, 2024

Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting

CLINICAL STUDY

CALENDAR OF EVENTS

Jun 14, 2024

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

DIRECTORS AND OFFICERS

May 23, 2024

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

CLINICAL STUDY

Feb 22, 2024

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis